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Matrix metalloproteinases (MMPs) are endopeptidases 
involved in the proteolysis of extracellular matrix (ECM) 
proteins [1]. The ECM is considered an important determinant 
for the axial length of the eye. The enhanced activation of 
collagen degrading enzymes, particularly MMPs, might play 
a role in the remodeling of the ECM during ocular growth and 
development. Abnormal expression of MMPs in the eye has 
been implicated in many disorders, including glaucoma [2,3], 
proliferative vitreoretinopathy [4-6], cataract formation [7], 
and pterygia [8,9]. Scholtzer Schrehardt et al. [10] observed 
that decreased activity of MMPs in the aqueous humor might 
be involved in the abnormal accumulation of the matrix found 
in pseudoexfoliation glaucoma (PEXG) and POAG.
Twenty-six MMPs have been discovered, which are 
grouped into five main classes (collagenases, gelatin-
ases, stromelysins, membrane-type, and others, including 
matrilysin), based on substrate specificity, homology, and 
subcellular localization [11]. These MMPs are regulated by 
activation of latent MMPs and their inhibitors, commonly 
known as tissue inhibitors of metalloproteinases, but it is 
believed that regulation at the transcriptional level has a 
greater impact on the expression of these MMPs. Expression 
studies revealed that most MMP genes are expressed at the 
time of tissue remodeling [11]. MMP-1, -2, -3, -9, and -14 have 
been shown to be expressed in the human sclera.
A cluster of MMP genes (MMP1, MMP3, MMP7, MMP8, 
MMP10, MMP12, MMP13, MMP20, MMP27) is localized 
on 11q22. Single nucleotide polymorphisms (SNPs) in the 
promoter region of various MMPs have been shown to 
affect transcription levels [12]. Insertion of a G nucleotide 
at position −1607 in the MMP1 promoter region has been 
observed in the core recognition sequence of a transcription 
factor binding site, which consequently modifies the level 
of MMP-1 expression [13]. It has been demonstrated that 
the promoter containing the 2G allele has a significantly 
higher transcriptional activity than that with the 1G allele 
[14]. Similarly, a transition from A to G at position −181 in 
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Purpose: Matrix metalloproteinases (MMPs) play an important role in remodeling of the extracellular matrix during 
development and growth of various tissues including the eye. Various functional polymorphisms in MMPs have been 
implicated in the pathogenesis of different types of glaucoma. The aim of the present study was to investigate the role 
of various polymorphisms in Pakistani patients with glaucoma.
Methods: The present case-control study included 112 patients with primary open-angle glaucoma (POAG), 82 patients 
with primary angle closure glaucoma (PACG), and 118 control subjects. Genotyping of polymorphisms was done using 
PCR followed by restriction fragment length polymorphism analysis.
Results: A significant difference in the genotype frequencies of MMP1 rs1799750 (−1607 1G/2G) was observed between 
the patients with POAG and the control subjects (p=0.001). This was attributed to the female subjects (p<0.001), while the 
association was not significant in male subjects (p>0.47). In addition, a significant difference was observed in genotype 
frequencies of MMP9 rs17576 (c.836A>G) in patients with PACG compared to the control subjects (p<0.001), which 
after gender stratification remained significant in men (p=0.009) but not in women (p=0.14). No significant associations 
were found for MMP7 (c.-181T>C) and MMP9 (c.-1562C>T) polymorphisms.
Conclusions: Our data suggest that the MMP1 rs1799750 (−1607 1G/2G) and MMP9 rs17576 polymorphisms might be 
of value for further study as potential gender-dependent risk factors for developing POAG and PACG, respectively, in 
Pakistan.
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the promoter region of the MMP7 gene has been reported to 
result in abnormal activity of MMP-7 [15]. Various functional 
variants have been identified in the MMP9 gene, located on 
20q11.2-q13.1 [16-18]. The −1562C>T polymorphism in the 
promoter region exerts a functional effect on gene transcrip-
tion. Another polymorphism in MMP9, 836A>G (rs17576), 
affects the substrate-binding domain of the MMP-9 enzyme, 
substituting an uncharged amino acid (glutamine) by a posi-
tively charged amino acid (arginine). This polymorphism 
likely alters the protein conformation, leading to a change in 
the substrate-binding and enzyme activity [13]. These four 
SNPs in MMP1, MMP7, and MMP9 have been studied in 
various types of glaucoma in different populations [19,20]. 
The aim of the current study was to determine whether the 
polymorphisms in the promoter and coding regions of MMP1, 
MMP7, and MMP9 are associated with POAG and PACG in a 
Pakistani population.
METHODS
Patients: All the patients were recruited from the glaucoma 
clinic of Al-Shifa Trust Eye Hospital in Rawalpindi. Patients 
were Punjabi in ethnicity (from the Punjab province, located 
in central Pakistan). The study group consisted of 312 indi-
viduals; 112 POAG cases, 82 PACG cases and 118 control 
subjects. The POAG patients had a mean age of 52.6±1.4 
years (69.6% males and 30.4% females), PCAG patients had 
a mean age of 53.6±1.5 years (males: 48.8%, females 51.2%) 
and control subjects had a mean age of 50.1±1.3 years (males: 
60.2%, females 39.8%). This study conforms to the tenets of 
the Helsinki declaration and was approved by the Depart-
mental Review and Ethics Committee. All subjects were 
briefed about the study in their local language, and written 
informed consent was obtained before their blood samples 
were obtained. The inclusion criteria for patients and controls, 
clinical examinations, and collection and processing of blood 
samples have been described previously [21]. Briefly, for 
patients with POAG, the inclusion criteria were high intra-
ocular pressure (IOP; >21 mmHg) measured using Goldmann 
applanation tonometry, a cup-to-disc ratio greater than 0.5, 
visual field defects typical of glaucoma, which were deter-
mined with a Humphrey Field Analyzer (Zeiss Humphery 
Systems, Dublin, CA), and an open anterior chamber angle. 
The diagnosis of angle closure was made with gonioscopy, 
which aids in identifying regions of apposition of the iris to 
the trabecular meshwork. IOP, cup-disc ratio, and visual field 
defects criteria for PACG were similar to POAG.
Genotyping of single nucleotide polymorphisms: Venous 
blood of patients and healthy individuals was drawn by veni-
puncture and collected in acid citrate dextrose vacutainers 
(Becton Dickinson, Franklin Lakes, NJ). Genomic DNA 
was extracted from whole blood using a standard phenol 
chloroform method [22] and used for genotyping. Genotypes 
were determined with PCR–restriction fragment length poly-
morphism (PCR–RFLP) analysis of the four SNPs studied in 
MMP1 rs1799750 (c.-1607–1606insGG), MMP7 rs11568818 
(c.-181T>C), and MMP9 (rs3918242 c.-1562C>T and rs17576 
c.836A>G; p.Gln279Arg). Sequences of the primers used for 
amplification of the four SNPs are given in Table 1. In the 
case of MMP1, a restriction enzyme site for AluI (AGCT) was 
introduced in the reverse primer by replacing a T with a G at 
the penultimate position. The 1G allele has this recognition 
site, whereas in the 2G allele this site is abolished due to the 
insertion of an additional guanine [23]. In the MMP7 reverse 
primer, a mismatch was introduced at the fourth-to-last 
base [15]. Annealing temperatures, sizes of PCR products, 
enzymes used for RFLP, and product sizes obtained after 
digestion are presented in Table 1 [15,23-25].
For genotyping of four SNPs MMP1 rs1799750; MMP7 
rs11568818, MMP9 (rs3918242 and rs17576), 16 µl aliquot of 
PCR product was subjected to restriction enzyme digestion 
at 37° C overnight with 10 U of AluI, EcoRI, SphI, and MspI 
restriction enzymes, respectively, according to the manufac-
turer’s instructions (Fermentas, Burlington, Canada). The 
resulting digested products were resolved on 3% agarose gels 
(Table 1).
Statistical analysis: The associations between the genotype 
and allele frequencies in patients compared to controls were 
analyzed by computing the Pearson chi-square (χ2) and odds 
ratio (OR 95% confidence interval, CI) using statistical 
software StatCalc EpiInfo package v.6 (Atlanta, GA). Power 
analysis was performed with G*Power software version 3.0.8.
RESULTS
Patients and controls included in the current study were age-
matched. The mean age of the controls was 37.9±10.8 years, 
of patients with POAG 39.5±12.4 years, and of patients with 
PACG 40.9±16.4 years. In total, 118 healthy subjects (71 men 
and 47 women), 112 patients with POAG (78 men and 34 
women), and 82 patients with PACG patients (40 men and 
42 women) were enrolled in the study. The majority of the 
patients were using medications such as β-blockers to lower 
IOP. Power calculation indicated that this study had sufficient 
sample size of controls and cases to detect the previously 
described effect sizes. Three upstream promoter polymor-
phisms in MMP1, MMP7, MMP9, and one non-synonymous 
SNP in MMP9 were genotyped. Genotype frequencies were 
consistent with the Hardy–Weinberg equilibrium (HWE) 
for all four SNPs. A significant difference in genotype 
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frequencies was found for the MMP1 (rs1799750; c.-1607–
1606insGG) SNP in patients with POAG and PACG compared 
to the controls (Table 2). The homozygous 2G/2G genotype 
was found at a significantly higher frequency in patients with 
POAG (OR 3.53 [95% CI=1.63–7.73]; p<0.001) and patients 
with PACG (OR 2.23 [95% CI=0.96–5.21]; p=0.04). A highly 
significant association was observed for the 2G allele and 
patients with POAG (OR 2.04 [95% CI=1.38–3.01); p<0.001]. 
A weaker association was observed between the 2G allele and 
patients with PACG (OR 1.61 [95% CI=1.05–2.47]); p=0.02; 
Table 3).
A significant association was observed between the GG 
genotype of the non-synonymous MMP9 variant (rs17576; 
c.836A>G; p.Gln279Arg) and patients with PACG (OR 3.73 
[95% CI=1.59–8.86]; p<0.001), and to a lesser extent with 
patients with POAG (OR=2.34 [95% CI=1.09–5.05]; p=0.01; 
Table 4). Similarly, the G allele was significantly associated 
with patients with PACG (OR 2.12; [95% CI=1.39–3.26]; p 
value <0.001) with a higher level of significance compared to 
patients with POAG (OR 1.60 [95% CI=1.09–2.35]; p=0.01; 
Table 5).
No significant associations were observed for the 
MMP7 (c.-181T>C) and MMP9 (c.-1562C>T) promoter 
polymorphisms.
Data were further stratified by gender to study gender-
specific associations. The MMP1 (c.-1607–1606insGG) 
SNP was found to be significantly associated with POAG 
(p<0.001, χ2=17.20) and PACG in female patients (p=0.03, 
χ2=6.94; Table 6). For MMP9, a significant association of 
the rs17576 SNP was observed with PACG in men (p=0.009, 
χ2=9.21; Table 7).
DISCUSSION
In the current study, we detected significant associations 
of MMP1 (c.-1607–1606insGG) and MMP9 polymorphisms 
(c.836A>G; p.Gln279Arg) with POAG and PACG respec-
tively. Both polymorphisms have been studied previously 
in patients with POAG and PACG in different populations. 
A significant association has been described between the 
homozygous 2G/2G genotype and POAG in a Polish popu-
lation (OR 1.73; [95% CI=1.05–2.86]; p=0.019) [26]. This is 
consistent with the current study, although the association 
Table 1. Primers and resTricTion enzymes used To genoTyPe mmP PolymorPhisms
SNP Forward primer C† PCR 
product
R. E RFLP fragments Ref
MMP-1=(rs1799750)  
c.-1607–1606insGG
TGACTTTTAAAACATAGTCTATGTTCA 
TCTTGGATTGATTTGAGATAAGTCATAGA
58 269 AluI 1G/1G=241,28 
2G/2G=269
 [23]
MMP-7=(rs11568818)  
c.-181T>C
TGGTACCATAATGTCCTGAATG 
TCGTTATTGGCAGGAAGCACACAATGAATT
65 150 EcoRI T=150 C=120,30  [15]
MMP-9=(rs3918242)  
c.-1562C>T
GCCTGG CACATAGTAGGCCC 
CTTCCTAGCCAGCCGGCATC
58 436 SphI C=436 T=242,194  [24]
MMP-9=(rs17576)  
c.836A>G
GAGAGATGGGATGAACTG 
GTGGTGGAAATGTGGTGT
58 439 MspI A=252,187 
G=187, 129, 123
 [25]
C†=annealing temperature; R.E=Restriction endonuclease
Table 2. MMP-1 and MMP-7 snP genoTyPe frequencies in Poag and Pacg PaTienTs and unaffecTed conTrols
Controls 
n=118 
(%)
POAG 
n=112 (%)
p (χ2) p (χ2) OR (95% CI)
PACG 
n=82 (%)
p (χ2) p (χ2) OR (95% CI)
MMP-1= c.-1607-1606insGG
1G/1G 53(44.9) 27(24)
0.001 
(13.04)
Reference 25(30.5)
0.09 
(4.75)
Reference
1G/2G 45(38.1) 49(44) 0.01 (5.93) 2.14 (1.10-4.15) 36(43.9) 0.10 (2.58) 1.70 (0.85-3.41)
2G/2G 20(17.0) 36(32) <0.001 (12.35) 3.53 (1.63-7.73) 21(25.6) 0.04 (4.16) 2.23 (0.96-5.21)
MMP-7 = c.-181T>C
TT 43(36.4) 36(32.1)
0.35 
(2.07)
Reference 24(29.3)
0.55 
(1.18)
Reference
TC 57(48.3) 64(57.1) 0.31 (1.03) 1.34 (0.73-2.47) 43(52.4) 0.35 (0.86) 1.35 (0.68-2.69)
CC 18(15.3) 12(10.8) 0.60 (0.27) 0.80 (0.31-2.03) 15(18.3) 0.35 (0.86) 1.49 (0.59-3.80)
Molecular Vision 2013; 19:441-447 <http://www.molvis.org/molvis/v19/441> © 2013 Molecular Vision 
444
detected in Pakistani patients with POAG is stronger (OR 3.53 
[95% CI=1.63–7.73]; p<0.001). The current study is the first to 
describe a significant association of this polymorphism with 
PACG, but the association is weaker than with POAG.
Previous studies observed significant associations 
between the MMP9 polymorphism (rs17576) and PACG in 
Taiwanese and Australian populations [27,28]. It has been 
proposed that the short axial length in PACG is perhaps due 
to an alteration in the activity of MMP-9 in the remodeling of 
ECM during ocular growth and development.
In a southern Chinese population, no significant associa-
tion was observed with PACG for rs17576, while a significant 
association was detected between rs2250889 in MMP9 and 
PACG (p=0.004). The MMP9 rs17576 polymorphism substi-
tutes a positively charged arginine by an uncharged gluta-
mine in a highly conserved gelatinase-specific fibronectin 
type II domain (FN2), one of three types of internal repeats 
that combine to form larger domains within fibronectin. This 
domain in MMP-9 is responsible for the collagen affinity 
of MMP-9 and presumably enhances substrate binding. 
Table 3. MMP-1 and MMP-7 snP allele frequencies in Poag and Pacg PaTienTs and unaffecTed conTrols
 Controls n=236 (%)
POAG 
n=224 (%) p (χ
2) OR (95% CI) PACG n=164 (%) p (χ
2) OR (95% CI)
MMP-1= c.-1607-1606insGG
1G 151(64.0) 103(46)
<0.001 (14.22) 2.04 (1.38-3.01)
86(52.4)
0.02 (4.57) 1.61 (1.05-2.47)
2G 85(36.0) 121(54.0) 78(47.6)
MMP-7 = c.-181T>C
T 143(60.6) 136(60.7)
0.97 (0.00) 0.99 (0.67-1.47)
91(55.5)
0.30 (1.04) 1.23 (0.81-1.89)
C 93(39.4) 88(39.3) 73(44.5)
Table 4. mmP-9 snP genoTyPe frequencies in Poag and Pacg PaTienTs and unaffecTed conTrols
Controls  
n=118 (%)
POAG  
n=112 
(%)
p (χ2) p (χ2) OR (95% CI) PACG  n=82 (%) p (χ
2) p (χ2) OR (95% CI)
MMP-9 = c.-1562C>T
CC 74(62.7) 70 (62.5)
0.24 
(2.85)
Reference 56(68.3)
0.23 
(2.93)
Reference
CT 37(31.3) 40(35.7) 0.22 (0.63) 1.14 (0.63-2.06) 25(30.5) 0.71 (0.13) 0.89 (0.46-1.73)
TT 7(6) 2(1.8) 0.12 (2.37) 0.30 (0.04-1.67) 1(1.2) 0.08 (2.91) 0.19 (0.01-0.60)
MMP-9 = c.836A>G 
AA 40 (33.9) 26(23.2)
0.05 
(5.75)
Reference 15(18.3)
<0.001 
(12.13)
Reference
AG 53(44.9) 48(42.9) 0.30 (1.07) 1.39 (0.71-2.75) 32(39.0) 0.20 (1.61) 1.61 (0.72-3.60)
GG 25(21.2) 38(33.9) 0.01 (5.64) 2.34 (1.09-5.05) 35(42.7) <0.001 (11.27) 3.73 (1.59-8.86)
Table 5. MMP-9 snP allele frequencies in Poag and Pacg PaTienTs and conTrols
 Controls n=236 (%)
POAG 
n=224 (%) p (χ
2) OR (95% CI) PACG n=164 (%) p (χ
2) OR (95% CI)
MMP-9 = c.-1562C>T
C 185(78.4) 180(80.4)
0.60 (0.27) 0.89 (0.55-1.43)
137(83.5)
0.20 (1.63) 0.71 (0.41-1.23)
T 51(21.6) 44(19.6) 27(16.5)
MMP-9 = c.836A>G
A 133(56.4) 100(44.6)
0.01 (6.31) 1.60 (1.09-2.35)
62(37.8)
<0.001 (13.33) 2.12 (1.39-3.26)
G 103(43.6) 124(55.4) 102(62.2)
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These residues might have significant interactions with the 
surrounding residues, so variations in this amino acid could 
affect protein stability and function [29-31]. In the present 
study, a significant association of rs17576 SNP was found 
with male patients with PACG. Naturally occurring sexual 
dimorphism has been implicated in the risk and progression 
of neurodegenerative diseases schizophrenia, Parkinson 
disease, and Alzheimer disease [32,33]. Various previous 
studies suggest that these differences between men and 
women could result from estrogens that downregulate the 
production and/or release of proinflammatory cytokines such 
as tumor necrosis factor alpha (TNF-α) [31]. The transcription 
of MMP genes in turn is enhanced by proinflammatory cyto-
kine TNF-α [34]. This male-specific association could also 
be reconciled with evidence that women have constitutively 
a lowered innate immune response [35].
MMP levels in the aqueous humor have previously been 
found to be significantly raised in patients with POAG and 
PEXG [36]. Experiments were performed by Ito et al. [37] 
to determine the effect of antiglaucoma drugs on metabo-
lism within the extracellular matrix of the ocular surface, 
including the corneal, conjunctival, and subconjunctival areas 
in the rat. That study suggests that αβ-blockers, α1-blockers, 
α2-agonists, and prostaglandin derivatives may stimulate 
ECM degradation of the ocular surface tissue by modu-
lating the balance between MMPs and their inhibitors in 
the progression of glaucoma, when they are not functioning 
properly [37]. The precise impact of these polymorphisms on 
the function of the protein is still unknown, but they could 
be involved in the partial loss of function of the ECM remod-
eling during the development and growth of the eye.
In conclusion, our results revealed a significant associa-
tion of MMP1 rs1799750 (-1607 1G/2G) and MMP9 (rs17576) 
polymorphisms with POAG and PACG, respectively, in a 
Pakistani population. Additional studies are required to 
understand the exact role of these polymorphisms in the 
pathogenesis of glaucoma.
Table 6. MMP-1 and MMP-7 snPs genoTyPe frequencies wiTh resPecT To gender 
in Poag and Pacg PaTienTs and unaffecTed conTrols
Males Females
Controls  
n=71 (%)
POAG n=78 
(%) p (χ
2) PACG n=40 (%) p (χ
2) Controls  n=47 (%)
POAG  
n=34 (%)
p (χ2) PACG n=42 
(%)
p (χ2)
MMP-1= c.-1607-1606insGG
1G/1G 24 (33.8) 20 (25.6)
0.47 
(1.48)
10 (25.0)
0.51 
(1.34)
29 (61.7) 7 (20.6)
<0.001 
(17.20)
15 (35.7)
0.03 
(6.94)1G/2G 30 (42.3) 34 (43.6) 17 (42.5) 15 (31.9) 15 (44.1) 19 (45.2)
2G/2G 17 (23.9) 24 (30.8) 13 (32.5) 3 (6.4) 12 (35.3) 8 (19.1)
MMP-7 = c.-181T>C
TT 28 (39.4) 22 (28.2)
0.18 
(3.33)
9 (22.5)
 0.10 
(4.47)
15 (31.9) 14 (41.2)
0.68 
(0.75)
15 (35.7)
0.68 
(0.74)TC 35 (49.3) 50 (64.1) 22 (55.0) 22 (46.8) 14 (41.2) 21 (50.0)
CC 8 (11.3) 6 (7.70) 9 (22.5) 10 (21.3) 6 (17.6) 6 (14.3)
Table 7. MMP-9 snPs genoTyPe frequencies wiTh resPecT To gender in Poag and Pacg PaTienTs and unaffecTed conTrols
Males Females
Controls  
n=71 (%)
POAG  
n=78 (%) p (χ
2) PACG  n=40 (%) p (χ
2) Controls  n=47 (%)
POAG  
n=34 (%) p (χ
2) PACG  n=42 (%) p (χ
2)
MMP-9 = c.-1562C>T
CC 42 (59.2) 49 (62.8)
0.43  
(1.68)
26 (65.0)
0.22  
(2.97)
32 (68.1) 21 (61.8)
0.32  
(2.25)
30 (71.4)
0.86  
(0.28)CT 24 (33.8) 27 (34.6) 14 (35.0) 13 (27.7) 13 (38.2) 11 (26.2)
TT 5 (7.0) 2 (2.6) 0 (0.00) 2 (4.2) 0 (0.00) 1 (2.4)
MMP-9 = c.836A>G
AA 24 (33.8) 21 (26.9)
0.28  
(2.51)
5 (12.5)
 0.009  
(9.21)
16 (34.0) 5 (14.7)
0.08  
(4.88)
10 (23.8)
0.14  
(3.86)AG 33 (46.5) 33 (42.3) 18 (45.0) 20 (42.6) 15 (44.1) 14 (33.3)
GG 14 (19.7) 24 (30.8) 17 (42.5) 11 (23.4) 14 (41.2) 18 (42.9)
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